Clinical Trials

Double Blind, Placebo-controlled Oral Medication for the treatment of Moderate to Severe Chronic Plaque Psoriasis

Greenwich Village Dermatology is looking for adults who have chronic moderate to severe psoriasis to participate in a research study.  To qualify, you must currently have moderate to severe psoriasis- thickened patches of red inflamed skin covered with a silvery white buildup of dead skin cells or “scales” that can be itchy, painful and may crack or bleed. There is no cost to you, and you may be compensated for your time. Health insurance is not needed.

Click the link below for more info on this trial.

Clinical Trial for Mild to Moderate Atopic Dermatitis:

Are you or someone you know suffering from mild to moderate atopic dermatitis? We’re excited to announce a new 8-week clinical trial designed for patients aged 12 and over who are grappling with this condition. Our study aims to rigorously evaluate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% and OPZELURA(TM) (Ruxolitinib) Cream in treating mild-to-moderate atopic dermatitis.

To be eligible for this trial, you should meet the following criteria:

• Have a confirmed diagnosis of Atopic Dermatitis (eczema) for a minimum of 2 years.
• Experience Atopic Dermatitis on 3 to 20% of your body.
• Be willing to keep all other topical cosmetic or skin maintenance products (excluding the study product) the same during the study.
• Compensation of up to $200 for time and travel may be provided. Your participation in this clinical trial comes at no cost to you.

Clinical Trial for Alopecia Areata Research:

Alopecia Areata, often characterized by coin-shaped patches of hair loss on the face, scalp, or body, can be a challenging condition. Here’s an opportunity to contribute to advancing research in this field. We are looking for participants aged 18 to 75 with severe to very severe Alopecia Areata to join our clinical trial.

To qualify, you should have:

• A clinical diagnosis of severe to very severe Alopecia Areata.
• Experienced hair loss for more than 6 months but less than 10 years.
• Commitment to maintaining the same hairstyle and color throughout the trial.
• Participants may receive compensation of up to $2,100 for time and travel. Your participation in this clinical trial is cost-free.

Treatment for Moderate to Severe Atopic Dermatitis:

If you’ve tried various treatments for moderate to severe atopic dermatitis without success, we have a new avenue to explore. Our clinical trial is seeking adult patients for a study that assesses the safety and efficacy of a twice-monthly injection for this condition.

To be eligible for this study, you should:

• Be a healthy adult aged 18 to 75.
• Have a diagnosis of moderate to severe atopic dermatitis for at least 6 months.
• Experience atopic dermatitis affecting at least 20% of your body.
• Have had an inadequate response to topical treatments for atopic dermatitis.
• Compensation of up to $1,200 for time and travel may be provided. Your participation in this clinical trial is cost-free.

Research Study for Cutaneous Squamous Cell Carcinoma (cSCC):

Cutaneous squamous cell carcinoma (cSCC) is a prevalent form of skin cancer, but early detection can make a significant difference. We are conducting a 4-year research study focused on patients with invasive cSCC. This study aims to identify those at risk of skin cancer spread (metastasis) within three years of diagnosis.

Our study involves the DecisionDx®-SCC gene expression assay to categorize patients into risk groups. Your participation will help us understand outcomes related to cSCC and the usefulness of this test.

Observational Study on Immune-Mediated Inflammatory Skin Conditions (IMISC):

Join our observational study designed to gain insights into the treatment regimens and patient outcomes of a group of inflammatory skin conditions (known as Immune-Mediated Inflammatory Skin Conditions (IMISC)). We are specifically looking for participants with Atopic Dermatitis, Hidradenitis suppurativa, Alopecia Areata, and Urticaria to represent a broad spectrum of the IMISC patient community. Your involvement will contribute to advancing our understanding of these conditions.